.
MergerLinks Header Logo

Announced

Completed

Ipsen completed the acquisition of Epizyme for $247m.

Financials

Transaction Value

£201m

Consideration Type

Cash

Contingent Deferred Consideration

Capital Owned

+ Add

Capital bid for

100%

EV/Sales

+ Add

EV/EBITDA

+ Add

Share Price Premium

144%

Transaction Tags

Public

Friendly

Biotechnology

United States

Privatisation

biopharmaceuticals

Majority

Single Bidder

Acquisition

Cross Border

Completed

Synopsis

Ipsen, a biopharmaceutical company, completed the acquisition of Epizyme, a commercial-stage biopharmaceutical company, for $247m. “Throughout the pre-close phase of planning, we have continued to be impressed by the potential of Tazverik, as well as the rest of the pipeline. Now that the deal is closed, we are excited to be working closely with our Epizyme colleagues to leverage Ipsen’s established infrastructure so that these medicines may reach more patients. Additionally, through this transaction Ipsen gains scientific expertise and we look forward to integrating the two teams which share the goal of delivering innovative treatment options to underserved patients," David Loew, Ipsen CEO.

Sources

Press Release

Epizyme

Completion Announcement

Ipsen

Financials

Transaction Value

£201m

Consideration Type

Cash

Contingent Deferred Consideration

Capital Owned

+ Add

Capital bid for

100%

EV/Sales

+ Add

EV/EBITDA

+ Add

Share Price Premium

144%

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US